At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
delgocitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 1 clinical trial evaluating delgocitinib for Atopic Dermatitis. Completed, enrolled 46 participants across 16 sites in 2 countries.
Detailed Summary
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionOct 2021
TodayJul 2026
First PostedFeb 1, 2019
Enrollment StartFeb 20, 2019
Primary CompletionOct 29, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.4 years ago
Interventions
delgocitinibdrug
Cream for topical application